The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 16, Issue 8, Pages 673-688
Publisher
Wiley
Online
2013-12-24
DOI
10.1111/dom.12251
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2013) Lesley J. Scott BIODRUGS
- Incretin Therapy and Islet Pathology: A Time for Caution
- (2013) S. E. Kahn DIABETES
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter
- (2013) P. Valensi et al. DIABETOLOGIA
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
- (2013) Paulus Wohlfart et al. Journal of Translational Medicine
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells
- (2012) Aya Shiraki et al. ATHEROSCLEROSIS
- Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells
- (2012) Özlem Erdogdu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTcinterval in healthy subjects
- (2012) Börje Darpö et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Improvement of psoriasis during exenatide treatment in a patient with diabetes
- (2012) M. Buysschaert et al. DIABETES & METABOLISM
- Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
- (2012) Concetta Irace et al. Diabetes & Vascular Disease Research
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
- (2012) K. Niswender et al. DIABETES OBESITY & METABOLISM
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
- (2012) Lina Han et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
- (2012) Michael Horowitz et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
- (2012) Carlos Alves et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- Acute tubulointerstitial nephritis following treatment with exenatide
- (2012) H. Nandakoban et al. DIABETIC MEDICINE
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study
- (2012) Flip J.P. Bernink et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Pancreatic Volume Is Reduced in Adult Patients with Recently Diagnosed Type 1 Diabetes
- (2012) Alistair J. K. Williams et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study
- (2012) T. Ahern et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats
- (2012) Wei-Na Han et al. NEUROBIOLOGY OF AGING
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide-Induced Acute Kidney Injury
- (2012) Yaman Kaakeh et al. PHARMACOTHERAPY
- Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection
- (2012) Hei-Jen Huang et al. PLoS One
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide
- (2011) A. Faurschou et al. ACTA DIABETOLOGICA
- The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
- (2011) Anne Flint et al. ADVANCES IN THERAPY
- Psoriasis increased the risk of diabetes: a meta-analysis
- (2011) Juan Cheng et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats
- (2011) Wei Jing Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
- (2011) T. Himeno et al. DIABETES
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
- (2011) Steven P Marso et al. Diabetes & Vascular Disease Research
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- (2011) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies
- (2011) Anthony Stonehouse et al. Diabetes Technology & Therapeutics
- Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
- (2011) D. J. Drucker et al. DIABETOLOGIA
- Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
- (2011) A. E. Hogan et al. DIABETOLOGIA
- Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
- (2011) Scott E. Kanoski et al. ENDOCRINOLOGY
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects
- (2011) H. Linnebjerg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
- (2011) A. Hamilton et al. JOURNAL OF NEUROSCIENCE RESEARCH
- The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
- (2011) Scott E. Kanoski et al. NEUROPHARMACOLOGY
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study
- (2011) Aaron S. Kelly et al. Obesity
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation
- (2011) Mukesh Punjabi et al. PHYSIOLOGY & BEHAVIOR
- Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
- (2011) Weike Bao et al. PLoS One
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
- (2010) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients
- (2010) Jason L. Gaglia et al. JOURNAL OF CLINICAL INVESTIGATION
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
- (2010) Alfonso López-Ruiz et al. PHARMACY WORLD & SCIENCE
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Exenatide-Associated Ischemic Renal Failure
- (2009) W. J. Weise et al. DIABETES CARE
- Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes
- (2009) Deepti Bulchandani et al. ENDOCRINOLOGIST
- Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
- (2009) Dhruba J. Chatterjee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- Incretin-based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
- (2009) Allison Wick et al. Journal of the American Academy of Nurse Practitioners
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE ε4
- (2008) Fumiko Irie et al. ARCHIVES OF NEUROLOGY
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
- (2008) David C. Klonoff et al. CURRENT MEDICAL RESEARCH AND OPINION
- Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
- (2008) J. A. Driver et al. DIABETES CARE
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome
- (2008) Karen Elkind-Hirsch et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?
- (2008) Christian Hölscher et al. NEUROBIOLOGY OF AGING
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now